A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.
A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.
CSI Paris Eline Groenland asks Dan Lane about his novel screening method using urine samples that can detect whether hypertensive patients take their drugs. This test may help to improve medical adherence.
ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.
In the AMBER trial, taking concomitant patiromer enabled more persistent use of spironolactone in patients with resistant hypertension and chronic kidney disease, by reducing the risk of hyperkalemia.
ESC 2019 A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.
In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.
ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.
An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.
First-in-class firibastat, a selective and specific inhibitor of brain aminopeptidase A, safely reduced BP in hypertensive, overweight patients of multiple ethnic origins.
Analysis of data of six randomized sham-controlled trials of renal sympathetic denervation, shows that RSD gave greater reduction in 24-h ambulatory, daytime ambulatory and office SBP and DBP.